Key Developments: Northwest Biotherapeutics Inc (NWBO.OQ)

NWBO.OQ on NASDAQ Stock Exchange Capital Market

4.83USD
4:00pm EDT
Price Change (% chg)

$-0.20 (-3.98%)
Prev Close
$5.03
Open
$5.03
Day's High
$5.05
Day's Low
$4.70
Volume
164,656
Avg. Vol
119,184
52-wk High
$10.60
52-wk Low
$3.10

Search Stocks

Latest Key Developments (Source: Significant Developments)

Northwest Biotherapeutics Inc completes closing of $17.5 million convertible note offering
Tuesday, 19 Aug 2014 02:44pm EDT 

Northwest Biotherapeutics Inc:Says that the $17.5 mln convertible note offering announced Aug. 14, has closed.Three-year notes have five pct interest rate and are convertible at $7.30 per share of common stock.Investors also have option, exercisable for 3 months, to purchase up to additional 30 pct of these notes on same terms.Proceeds from this offering will help support an increase in manufacturing capacity for Company's DCVax products, as well as company's ongoing Phase III and Phase I/II clinical trials.  Full Article

Northwest Biotherapeutics Inc announces pricing of $17.5 mln offering of convertible notes
Thursday, 14 Aug 2014 11:47am EDT 

Northwest Biotherapeutics Inc:Announced the pricing of $17.5 million aggregate principal amount of its unsecured convertible notes in a private placement.Says the Notes are initially convertible at $7.30 per share, a 10 pct premium above the closing market price of $6.64 per share on Aug. 13.Plans to use the offering proceeds to fund new manufacturing capacity in Europe and for general corporate purposes.  Full Article

Northwest Biotherapeutics Inc phase III trial initiated in Germany
Tuesday, 10 Jun 2014 08:15am EDT 

Northwest Biotherapeutics Inc:Says that it has initiated the Phase III trial of DCVax-L in Germany.Says the first site to open in Germany was a medical center in Dresden, which was initiated in late May.Says the company has now scheduled the full-day site initiations for three more sites during June and four further sites in July.  Full Article

Northwest Biotherapeutics Inc announces financing of up to $32 million
Thursday, 10 Apr 2014 08:15am EDT 

Northwest Biotherapeutics Inc:Entered into an agreement with a single institutional investor for a registered direct placement of up to $32 million.The stock purchase agreement provides for the sale of an initial $15 million of common stock at $6.60 per share (about 8.0 pct discount to the closing market price).The stock purchase agreement also provides a non-transferable Oversubscription Option for the investor to purchase up to $17 million of common stock at $7.50 per share (about 5.0 pct premium to the closing market price) during the twelve months following the initial closing.There are no warrants in the financing.The placement is expected to close on or before April 14.H.C. Wainwright & Co., LLC acted as the sole placement agent for the transaction.  Full Article

Northwest Biotherapeutics Inc enters into agreements for large-scale expansion of product manufacturing, handling and distribution
Monday, 27 Jan 2014 08:16am EST 

Northwest Biotherapeutics Inc:Says it has entered into a set of agreements for large-scale expansion of the manufacturing, storage, handling and distribution of its DCVax-L and DCVax-Direct products, development of infrastructure and key systems.Says also execution of product validation work required for any eventual regulatory approvals, with the company's long-time contract manufacturer, Cognate Bioservices, Inc.  Full Article

Northwest Biotherapeutics Inc Announces Pricing Of Public Offering Of Common Stock And Warrants
Wednesday, 20 Nov 2013 09:29am EST 

Northwest Biotherapeutics Inc announced the pricing of an underwritten public offering of 4,895,834 units at a public offering price of $4.80 per unit, resulting in gross proceeds of $23,500,000. Each unit consists of one share of common stock, and a warrant to purchase 0.5 shares of common stock at an exercise price of $6.00 per share. The warrants are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately. The offering is expected to close on November 25, 2013, subject to the satisfaction of customary closing conditions. Northwest has granted the underwriters a 30-day option to purchase up to 734,374 additional shares of common stock and/or additional warrants to purchase up to 367,187 shares of common stock to cover over-allotments, if any. Oppenheimer & Co. Inc. is acting as the sole book-running manager for the proposed offering.  Full Article

Northwest Biotherapeutics Inc Announces Proposed Public Offering Of Common Stock
Tuesday, 19 Nov 2013 06:05pm EST 

Northwest Biotherapeutics Inc announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants to purchase common stock are being offered as units. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Oppenheimer & Co. Inc. is acting as sole book-running manager for the proposed offering.  Full Article

Northwest Biotherapeutics Inc Announces Registered Direct Offering
Friday, 9 Aug 2013 08:45am EDT 

Northwest Biotherapeutics Inc announced that on August 8, 2013, it entered into an agreement with institutional investors, including an existing healthcare focused institutional investor and a dedicated healthcare mutual fund for a registered direct placement of $15 million of common stock at the price of $3.35 per share plus an additional over-allotment warrant, exercisable within 12 months, to sell an additional $3.75 million of common stock at the same price which, if exercised, would result in gross proceeds to the Company of $18.75 million.  Full Article

Northwest Biotherapeutics Inc Announces Auditor Change-Form 8-K
Wednesday, 31 Jul 2013 05:23pm EDT 

Northwest Biotherapeutics Inc reported in its Form 8-K that on July 25, 2013, Northwest Biotherapeutics, Inc. changed its independent registered public accounting firm from Peterson Sullivan LLP to Marcum LLP for the year ending December 31, 2013.  Full Article

Northwest Biotherapeutics Inc Initiates DCVax-Direct Phase I/II Trial For All Solid Tumor Cancers
Thursday, 13 Jun 2013 08:15am EDT 

Northwest Biotherapeutics Inc that its 60-patient Phase I/II clinical trial of DCVax-Direct for all inoperable solid tumor cancers has been initiated at The University of Texas MD Anderson Cancer Center in Houston, Texas. DCVax-Direct offers a potential new treatment option for the many clinical situations in which patients' tumors are considered inoperable either because of the location or type of cancer, or because of the spread of multiple tumors. The trial is expected to enroll groups or 'cohorts' of patients with numerous different types of cancers, including pancreatic, colon, liver, melanoma, and various other cancers. The trial is a combined Phase I and II trial. In the Phase I stage, the trial will test various dose levels of DCVax-Direct. The trial will then proceed directly into the Phase II stage to test the efficacy of the DCVax-Direct treatment. The primary endpoint for measurement of efficacy will be tumor regression (i.e., shrinkage or elimination).  Full Article

UPDATE 1-Northwest Bio drug for inoperable tumors safe so far -researcher

June 19 - An experimental Northwest Biotherapeutics Inc drug for inoperable tumors has shown no signs of toxicity in an ongoing safety trial being conducted at M.D. Anderson Cancer Center, the trial's researcher said on Thursday.

Search Stocks